NCT01633983

Methotrexate for Central Serous Chorioretinopathy Treatment Trial

Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Edward Averbukh · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Detailed description

Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the center of the macula in adults of working age. Though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few short retrospective series of beneficial effect of MTX on CSC were reported recently. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision in a prospective manner.

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	Methotrexate	7.5 mg per week p.o. escalating up to 15 mg per week
DRUG	Delayed treatment	Methotrexate 7.5 mg per week per os escalating to 15 mg per week

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-07-01
• Completion: 2015-07-01
• First posted: 2012-07-06
• Last updated: 2012-07-20

Locations

1 site across 1 country: Israel